Sunitinib, a multi-receptor tyrosine kinase inhibitor approved for the targeted treatment of RCC, has recently been reported to inhibit the activation of the MAP4K1 protein in vitro [28]. The gene discussed is MAP4K1; the disease is renal cell carcinoma.